Banner

News

Article

Upcoming US Pharma and Biotech Summit Spotlights Innovation, Challenges in Healthcare

Leaders in areas such as drug discovery, clinical development and market access will meet to discuss AI, failing life expectancy, and a new generation of talent.

On May 16, the Financial Times US Pharma and Biotech Summit will take place in New York. With more than 40 speakers expected to participate and representation from over 255 companies, the summit will focus on discussions around the following:

  • What can stakeholders do to address falling life expectancy in the United States?
  • How is AI being plugged into discovery models?
  • Are pharma workforces ready for a new generation of American talent?

Christopher Viehbacher, president, CEO for Biogen, will begin the conference with a keynote interview. Some of the sessions throughout the day will include:

  1. Soft landing, hard problems: This panel will focus on a new economic macro-cycle with profound implications for the drug industry.
  2. Tackling America’s life-expectancy crisis: This panel will be a debate regarding the drop of life expectancy over the past two decades.
  3. Funding pharma and biotech innovation: This panel dives into the high costs of funding experimental drugs and how companies come up with innovative ways to secure funding.

Speakers at the event include Robert Truckenmiller, SVP, Head of US Vaccines, GSK; Linda Fried, Dean and DeLamar Professor of Public Health, Columbia University; Amy West, head of US Digital Transformation and Innovation, Novo Nordisk, and many more.

As part of the MJH Life Sciences community, you can save 20% off on your in-person and digital pass with discount code MJH.

Related Videos
© drrobertkushner.com
© drrobertkushner.com
© drrobertkushner.com